-
Company Insights
New![]()
Innovation and Patenting activity of CSL Ltd Q3 2023
GlobalData, the industry analysis specialist, has released its latest company patent databook "Innovation and Patenting activity of CSL Ltd Q3 2023". The databook highlights patenting activity of the company in terms of growth in filings and grants, regions protected, impact of various themes, sector applicability of technologies protected. It provides contextual analysis of technical peers, their strategy, dominance (Grant share) and their recent activities. This is an on-demand databook that will be delivered upon request. The report will be delivered...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – CSL-787 in Bronchiectasis
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. CSL-787 in Bronchiectasis Drug Details: CSL-787 is under development for the treatment of non-cystic fibrosis...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – CSL-346 in Diabetic Nephropathy
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.CSL-346 in Diabetic Nephropathy Drug Details:CSL-346 (VEGF-B antagonist) is under development for the treatment of diabetic...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – CSL-346 in Lipid Disorders
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.CSL-346 in Lipid Disorders Drug Details:CSL-346 (VEGF-B antagonist) is under development for the treatment of diabetic...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – CSL-040 in Transplant Rejection
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. CSL-040 in Transplant Rejection Drug Details: CSL-040 is under development for the treatment of transplant...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Garadacimab in Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency)
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.Garadacimab in Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) Drug Details:Garadacimab (CSL-312) is under development...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Garadacimab in Idiopathic Pulmonary Fibrosis
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Garadacimab in Idiopathic Pulmonary Fibrosis Drug Details: Garadacimab (CSL-312) is under development for the treatment...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Garadacimab in Interstitial Lung Diseases (Diffuse Parenchymal Lung Disease)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Garadacimab in Interstitial Lung Diseases (Diffuse Parenchymal Lung Disease) Drug Details: Garadacimab (CSL-312) is under...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – EXS-617 in Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. EXS-617 in Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer) Drug...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – ARX-517 in Pancreatic Cancer
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.ARX-517 in Pancreatic Cancer Drug Details:ARX-517 is under development for the treatment of solid tumors including...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.